The world’s first lung cancer vaccine, known as CIMAvax-EGF, has entered clinical trials in seven countries, marking a major milestone in cancer treatment.
Unlike preventive vaccines, this is a therapeutic vaccine designed to treat existing lung cancer by targeting and neutralizing epidermal growth factor (EGF) — a protein that promotes the growth of cancer cells.
Developed in Cuba, the vaccine has already shown promising results in extending survival for patients with advanced non-small cell lung cancer (NSCLC).
Now, international clinical trials are being launched in the United States, United Kingdom, Japan, Cuba, Serbia, Bosnia and Herzegovina, and Colombia.
The U.S. trials are being led by Roswell Park Comprehensive Cancer Center in partnership with Cuban researchers.
This groundbreaking collaboration could offer a new path forward in cancer immunotherapy, particularly for one of the deadliest cancers globally.
If successful, the vaccine may significantly improve outcomes and quality of life for lung cancer patients around the world.
Unlike preventive vaccines, this is a therapeutic vaccine designed to treat existing lung cancer by targeting and neutralizing epidermal growth factor (EGF) — a protein that promotes the growth of cancer cells.
Developed in Cuba, the vaccine has already shown promising results in extending survival for patients with advanced non-small cell lung cancer (NSCLC).
Now, international clinical trials are being launched in the United States, United Kingdom, Japan, Cuba, Serbia, Bosnia and Herzegovina, and Colombia.
The U.S. trials are being led by Roswell Park Comprehensive Cancer Center in partnership with Cuban researchers.
This groundbreaking collaboration could offer a new path forward in cancer immunotherapy, particularly for one of the deadliest cancers globally.
If successful, the vaccine may significantly improve outcomes and quality of life for lung cancer patients around the world.
The world’s first lung cancer vaccine, known as CIMAvax-EGF, has entered clinical trials in seven countries, marking a major milestone in cancer treatment.
Unlike preventive vaccines, this is a therapeutic vaccine designed to treat existing lung cancer by targeting and neutralizing epidermal growth factor (EGF) — a protein that promotes the growth of cancer cells.
Developed in Cuba, the vaccine has already shown promising results in extending survival for patients with advanced non-small cell lung cancer (NSCLC).
Now, international clinical trials are being launched in the United States, United Kingdom, Japan, Cuba, Serbia, Bosnia and Herzegovina, and Colombia.
The U.S. trials are being led by Roswell Park Comprehensive Cancer Center in partnership with Cuban researchers.
This groundbreaking collaboration could offer a new path forward in cancer immunotherapy, particularly for one of the deadliest cancers globally.
If successful, the vaccine may significantly improve outcomes and quality of life for lung cancer patients around the world.
